Astrazeneca (AZN) EBITDA (2006 - 2026)
Astrazeneca (AZN) EBITDA from Mar 31, 2006 to Mar 31, 2026. The TTM Astrazeneca (AZN) EBITDA is $20B. You can adjust inflation or export chart.
All data is split-adjusted. You can find the most accurate data from the reports on the SEC official website. We recommend verify information using official company filings before making investment decisions.
Annual EBITDA
Quarterly EBITDA
Astrazeneca (AZN) EBITDA CAGR table
| Period | CAGR |
|---|---|
| 1 Year TTM | +27.40% |
| 3 Years TTM | +22.94% |
| 5 Years TTM | +18.02% |
| 10 Years TTM | +11.67% |
| All Time TTM | +3.90% |
Annual EBITDA change of Astrazeneca (AZN)
| Year | EBITDA | Change |
|---|---|---|
| 2026 | $5.67B | -71.39% |
| 2025 | $20B | +28.44% |
| 2024 | $15B | +15.02% |
| 2023 | $13B | +47.74% |
| 2022 | $9.09B | +77.68% |
| 2021 | $5.11B | -36.75% |
| 2020 | $8.08B | +20.44% |
| 2019 | $6.71B | -5.62% |
| 2018 | $7.11B | +7.38% |
| 2017 | $6.62B | -8.97% |
| 2016 | $7.28B | +4.54% |
| 2015 | $6.96B | +26.75% |
| 2014 | $5.49B | -34.18% |
| 2013 | $8.34B | -21.91% |
| 2012 | $11B | -30.57% |
| 2011 | $15B | +4.39% |
| 2010 | $15B | +5.69% |
| 2009 | $14B | +10.53% |
| 2008 | $13B | +26.81% |
| 2007 | $9.95B | +4.07% |
| 2006 | $9.56B | N/A |
Comparison Astrazeneca (AZN) five years EBITDA CAGR with competitors
Astrazeneca (AZN) five years EBITDA CAGR is 18.02%.
| Ticker | Name | five years EBITDA CAGR | Upside |
|---|---|---|---|
| LLY | Lilly(Eli) & Company | 30.95% | +71.73% |
| NVO | Novo Nordisk | 25.26% | +40.14% |
| GILD | Gilead Sciences Inc | 17.19% | -4.61% |
| BMY | Bristol-Myers Squibb Company | 13.61% | -24.51% |
| MRK | Merck & Co Inc | 10.17% | -43.60% |
| JNJ | Johnson & Johnson | 6.13% | -65.97% |
| NVS | Novartis AG | 5.31% | -70.51% |
| ABBV | Abbvie Inc | 4.99% | -72.30% |
| AMGN | AMGEN Inc | 4.42% | -75.49% |
| GRFS | Grifols SA | 2.72% | -84.88% |
| GSK | GSK Plc | 1.17% | -93.52% |